C3N-03662
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 64.97467488
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20110025.TNBC | — | E | 0.895 |
| 2 | TCGA-B6-A0I6-01A-11R-A034-07 | — | E | 0.892 |
| 3 | TCGA-21-5783-01A-41R-2187-07 | — | cohortMD1 | 0.892 |
| 4 | TCGA-51-4081-01A-01R-1100-07 | — | cohortSQ2 | 0.879 |
| 5 | TCGA-22-4593-01A-21R-1820-07 | — | cohortSQ1 | 0.872 |
| 6 | TCGA-AR-A0TP-01A-11R-A084-07 | — | E | 0.869 |
| 7 | C3L-02168 | — | cohortSQ2 | 0.867 |
| 8 | TCGA-43-6770-01A-11R-1820-07 | — | cohortSQ2 | 0.857 |
| 9 | TCGA-AN-A0FX-01A-11R-A034-07 | — | E | 0.841 |
| 10 | 20130126.TNBC | — | E | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.520 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |